Wang H P, Wu H Y, Wang Y, Wang L
Obstetrics Department, Henan Provincial People’s Hospital, Zhengzhou, China
J Biol Regul Homeost Agents. 2017 Jul-Sep;31(3):691-695.
In recent years, gynecologic cancer has become the third leading cause of death for women world-wide. Serum tumor markers and inflammatory factors have been shown to be useful in the diagnosis of gynecological tumors. Therefore, the clinical value of the combined detection of tumor markers and serum inflammatory factors in the diagnosis of gynecologic oncology was studied. One hundred patients with gynecological tumors admitted to our hospital were selected as the tumor group, and 50 healthy volunteers were selected as the control group. According to clinical diagnosis, the tumor group was divided into a malignant tumor group and a benign tumor group. The levels of CA199, CA125, and CEA in each serum were measured by the Elecsys2010 automatic electrochemiluminescence immunoassay system. The levels of serum TNF-α and IL-17 were determined by enzyme-linked immunosorbent assay (ELISA). Our results showed that, when compared with the control group, the levels of CA199, CA125, CEA, TNF-α, and IL-17 in serum of the benign tumor group were significantly increased (P<0.001), and were further increased in the malignant tumor group. Moreover, the positive detection rates of combined detection of CA199, CA125, CEA, TNF-α, and IL-17 for malignant and benign tumors were significantly higher than that of single detection (P<0.05), and the positive detection rate of combined detection of malignant tumors was significantly higher than that of benign tumors (P<0.05). These results indicate that the combined detection of inflammatory factors and tumor markers has a high clinical value in the diagnosis and treatment of gynecological tumors and is worth adopting.
近年来，妇科癌症已成为全球女性的第三大死因。血清肿瘤标志物和炎症因子已被证明在妇科肿瘤的诊断中具有重要作用。因此，本研究探讨了肿瘤标志物与血清炎症因子联合检测在妇科肿瘤诊断中的临床价值。选取我院收治的100例妇科肿瘤患者作为肿瘤组，选取50例健康志愿者作为对照组。根据临床诊断，肿瘤组分为恶性肿瘤组和良性肿瘤组。采用Elecsys2010全自动电化学发光免疫分析系统检测各血清中CA199、CA125和CEA的水平。采用酶联免疫吸附试验（ELISA）检测血清TNF-α和IL-17水平。结果显示，与对照组相比，良性肿瘤组血清中CA199、CA125、CEA、TNF-α和IL-17水平显著升高（P<0.001），恶性肿瘤组进一步升高。此外，CA199、CA125、CEA、TNF-α和IL-17联合检测对恶性和良性肿瘤的阳性检出率显著高于单项检测（P<0.05），恶性肿瘤联合检测的阳性检出率显著高于良性肿瘤（P<0.05）。这些结果表明，炎症因子与肿瘤标志物联合检测在妇科肿瘤的诊断和治疗中具有较高的临床价值，值得推广应用。
